全文获取类型
收费全文 | 2892篇 |
免费 | 172篇 |
国内免费 | 23篇 |
专业分类
耳鼻咽喉 | 20篇 |
儿科学 | 79篇 |
妇产科学 | 54篇 |
基础医学 | 416篇 |
口腔科学 | 36篇 |
临床医学 | 265篇 |
内科学 | 531篇 |
皮肤病学 | 112篇 |
神经病学 | 173篇 |
特种医学 | 265篇 |
外科学 | 421篇 |
综合类 | 25篇 |
预防医学 | 197篇 |
眼科学 | 28篇 |
药学 | 220篇 |
中国医学 | 1篇 |
肿瘤学 | 244篇 |
出版年
2023年 | 13篇 |
2022年 | 30篇 |
2021年 | 60篇 |
2020年 | 27篇 |
2019年 | 45篇 |
2018年 | 36篇 |
2017年 | 52篇 |
2016年 | 54篇 |
2015年 | 58篇 |
2014年 | 70篇 |
2013年 | 110篇 |
2012年 | 143篇 |
2011年 | 144篇 |
2010年 | 116篇 |
2009年 | 117篇 |
2008年 | 119篇 |
2007年 | 148篇 |
2006年 | 121篇 |
2005年 | 120篇 |
2004年 | 107篇 |
2003年 | 91篇 |
2002年 | 85篇 |
2001年 | 77篇 |
2000年 | 63篇 |
1999年 | 55篇 |
1998年 | 58篇 |
1997年 | 52篇 |
1996年 | 51篇 |
1995年 | 48篇 |
1994年 | 26篇 |
1993年 | 40篇 |
1992年 | 46篇 |
1991年 | 45篇 |
1990年 | 45篇 |
1989年 | 43篇 |
1988年 | 48篇 |
1987年 | 37篇 |
1986年 | 41篇 |
1985年 | 39篇 |
1984年 | 25篇 |
1983年 | 31篇 |
1982年 | 31篇 |
1981年 | 18篇 |
1980年 | 17篇 |
1978年 | 16篇 |
1977年 | 21篇 |
1976年 | 23篇 |
1975年 | 23篇 |
1970年 | 13篇 |
1968年 | 17篇 |
排序方式: 共有3087条查询结果,搜索用时 15 毫秒
1.
Zhenzhen Zhang Mark Garzotto Tomasz M. Beer Philippe Thuillier Stephen Lieberman Motomi Mori 《Nutrition and cancer》2016,68(8):1309-1319
Animal and human studies suggest fish oil and green tea may have protective effect on prostate cancer. Fatty acid synthase (FAS) has been hypothesized to be linked to chemoprotective effects of both compounds. This study evaluated the independent and joint effects of fish oil (FO) and green tea supplement (epigallocatechin-3-gallate, EGCG) on FAS and Ki-67 levels in prostate tissue. Through a double-blinded, randomized controlled trial with 2 × 2 factorial design, 89 men scheduled for repeat prostate biopsy following an initial negative prostate biopsy were randomized into either FO alone (1.9 g DHA + EPA/day), EGCG alone (600 mg/day), a combination of FO and EGCG, or placebo. We used linear mixed-effects models to test the differences of prostate tissue FAS and Ki-67 by immunohistochemistry between pre- and post-intervention within each group, as well as between treatment groups. Results did not show significant difference among treatment groups in pre-to-post-intervention changes of FAS (P = 0.69) or Ki-67 (P = 0.26). Comparing placebo group with any of the treatment groups, we did not find significant difference in FAS or Ki-67 changes (all P > 0.05). Results indicate FO or EGCG supplementation for a short duration may not be sufficient to produce biologically meaningful changes in FAS or Ki-67 levels in prostate tissue. 相似文献
2.
3.
4.
5.
6.
7.
M. S. Beer J. A. Stanton Y. Bevan A. Heald A. J. Reeve L. J. Street V. G. Matassa R. J. Hargreaves D. N. Middlemiss 《British journal of pharmacology》1993,110(3):1196-1200
1. The 5-hydroxytryptamine (5-HT) receptor binding selectivity profile of a novel, potent 5-HT1D receptor agonist, L-694,247 (2-[5-[3-(4-methylsulphonylamino)benzyl-1,2,4-oxadiazol-5-yl ]- 1H-indole-3-yl]ethylamine) was assessed and compared with that of the 5-HT1-like receptor agonist, sumatriptan. 2. L-694,247 had an affinity (pIC50) of 10.03 at the 5-HT1D binding site and 9.08 at the 5-HT1B binding site (sumatriptan: pIC50 values 8.22 and 5.94 respectively). L-694,247 retained good selectivity with respect to the 5-HT1A binding site (pIC50 = 8.64), the 5-HT1C binding site (6.42), the 5-HT2 binding site (6.50) and the 5-HT1E binding site (5.66). The pIC50 values for sumatriptan at these radioligand binding sites were 6.14, 5.0, < 5.0 and 5.64 respectively. Both L-694,247 and sumatriptan were essentially inactive at the 5-HT3 recognition site. 3. L-694,247, like sumatriptan, displayed a similar efficacy to 5-HT in inhibiting forskolin-stimulated adenylyl cyclase in guinea-pig substantia nigra although L-694,247 (pEC50 = 9.1) was more potent than sumatriptan (6.2) in this 5-HT1D receptor mediated functional response. L-694,247 (pEC50 = 9.4) was also more potent than sumatriptan (6.5) in a second 5-HT1D receptor mediated functional response, the inhibition of K(+)-evoked [3H]-5-HT release from guinea-pig frontal cortex slices.(ABSTRACT TRUNCATED AT 250 WORDS) 相似文献
8.
Biodistribution and pharmacokinetics of the alphavbeta3-selective tracer 18F-galacto-RGD in cancer patients. 总被引:5,自引:0,他引:5
Ambros J Beer Roland Haubner Michael Goebel Stephan Luderschmidt Mary E Spilker Hans-Jürgen Wester Wolfgang A Weber Markus Schwaiger 《Journal of nuclear medicine》2005,46(8):1333-1341
(18)F-Galacto-RGD has been developed for PET of alpha(v)beta(3) integrin expression, a receptor involved in, for example, angiogenesis and metastasis. Our aim was to study the kinetics and biodistribution of (18)F-Galacto-RGD in cancer patients. METHODS: Nineteen patients with metastases of malignant melanoma (n = 7), sarcomas (n = 10), or osseous metastases (n = 2) were examined. After injection of 133-200 MBq (18)F-Galacto-RGD, 3 consecutive emission scans from the pelvis to the thorax or dynamic emission scans of the tumor over 60 min, followed by 1 static emission scan of the body, were acquired. Time-activity curves and standardized uptake values (SUVs) were derived by image region-of-interest analysis with image-based arterial input functions. Compartmental modeling was used to derive the distribution volume for muscle tissue and tumors. RESULTS: (18)F-Galacto-RGD showed rapid blood clearance and primarily renal excretion. SUVs in tumors ranged from 1.2 to 9.0. Tumor-to-blood and tumor-to-muscle ratios increased over time, with peak ratios of 3.1 +/- 2.0 and 7.7 +/- 4.3, respectively, at 72 min. The tumor kinetics were consistent with a 2-tissue compartment model with reversible specific binding. Distribution volume values were, on average, 4 times higher for tumor tissue (1.5 +/- 0.8) than those for muscle tissue (0.4 +/- 0.1). The data suggest that there was only minimal free and bound (specific or nonspecific) tracer in muscle tissue. CONCLUSION: (18)F-Galacto-RGD demonstrates a highly favorable biodistribution in humans with specific receptor binding. Most important, this study shows that (18)F-Galacto-RGD allows visualization of alpha(v)beta(3) expression in tumors with high contrast. Consequently, this tracer offers a new strategy for noninvasive monitoring of molecular processes and may supply helpful information for planning and controlling of therapeutic approaches targeting the alpha(v)beta(3) integrin. 相似文献
9.
Hermann J Girschick Etienne Mornet Meinrad Beer Monika Warmuth-Metz Peter Schneider 《BMC pediatrics》2007,7(1):3
Background
Hypophosphatasia (HP) is characterized by a genetic defect in the tissue-nonspecific alkaline phosphatase (TNSALP) gene and predominantly an autosomal recessive trait. HP patients suffer from reduced bone mineralization. Biochemically, elevated concentrations of substrates of TNSALP, including pyridoxal-5'-phosphate and inorganic pyrophosphate occur in serum, tissues and urine. The latter has been associated with chronic inflammation and hyperprostaglandinism. 相似文献10.